Literature DB >> 36033147

Stem Cell Therapies for Intraocular Disease.

P Kumar Rao1.   

Abstract

Irreversible blindness resulting from retinal or optic nerve diseases continues to devastate patients. The use of stem cell technology to reverse blindness promises great individual and societal benefit. Stem cell therapies seek to replace or enhance the function of damaged tissues. Currently, there are no FDA approved and commercially available products in this arena. Numerous clinical trials are underway, but as of today, we are still awaiting rigorous study data. Meanwhile, physicians and patients are desperate to restore vision and are lured to clinics claiming success. It remains our duty to vet these claims and guide our patients with their best interests in mind. Copyright 2022 by the Missouri State Medical Association.

Entities:  

Mesh:

Year:  2022        PMID: 36033147      PMCID: PMC9312444     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


  17 in total

Review 1.  The tumorigenicity of human embryonic and induced pluripotent stem cells.

Authors:  Uri Ben-David; Nissim Benvenisty
Journal:  Nat Rev Cancer       Date:  2011-03-10       Impact factor: 60.716

2.  Intravitreal autologous bone marrow CD34+ cell therapy for ischemic and degenerative retinal disorders: preliminary phase 1 clinical trial findings.

Authors:  Susanna S Park; Gerhard Bauer; Mehrdad Abedi; Suzanne Pontow; Athanasios Panorgias; Ravi Jonnal; Robert J Zawadzki; John S Werner; Jan Nolta
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-12-09       Impact factor: 4.799

3.  Dental pulp stem cells differentiation into retinal ganglion-like cells in a three dimensional network.

Authors:  Reza Roozafzoon; Alireza Lashay; Mohammad Vasei; Jafar Ai; Ahad Khoshzaban; Saeed Heidari Keshel; Zahra Barabadi; Hoda Bahrami
Journal:  Biochem Biophys Res Commun       Date:  2014-12-24       Impact factor: 3.575

4.  Vision Loss after Intravitreal Injection of Autologous "Stem Cells" for AMD.

Authors:  Ajay E Kuriyan; Thomas A Albini; Justin H Townsend; Marianeli Rodriguez; Hemang K Pandya; Robert E Leonard; M Brandon Parrott; Philip J Rosenfeld; Harry W Flynn; Jeffrey L Goldberg
Journal:  N Engl J Med       Date:  2017-03-16       Impact factor: 91.245

5.  Intravitreal injection of autologous bone marrow-derived mononuclear cells for hereditary retinal dystrophy: a phase I trial.

Authors:  Rubens C Siqueira; André Messias; Julio C Voltarelli; Ingrid U Scott; Rodrigo Jorge
Journal:  Retina       Date:  2011-06       Impact factor: 4.256

6.  Restoration of visual responses following transplantation of intact retinal sheets in rd mice.

Authors:  S Arai; B B Thomas; M J Seiler; R B Aramant; G Qiu; C Mui; E de Juan; S R Sadda
Journal:  Exp Eye Res       Date:  2004-09       Impact factor: 3.467

7.  A comparison of autologous transplantation of retinal pigment epithelium (RPE) monolayer sheet graft with RPE-Bruch's membrane complex graft in neovascular age-related macular degeneration.

Authors:  Yao Lu; Liang Han; Changguan Wang; Hongliang Dou; Xuefeng Feng; Yuntao Hu; Kang Feng; Xin Wang; Zhizhong Ma
Journal:  Acta Ophthalmol       Date:  2016-08-06       Impact factor: 3.761

8.  Retinal repair by transplantation of photoreceptor precursors.

Authors:  R E MacLaren; R A Pearson; A MacNeil; R H Douglas; T E Salt; M Akimoto; A Swaroop; J C Sowden; R R Ali
Journal:  Nature       Date:  2006-11-09       Impact factor: 49.962

9.  Neuroprotective Effects of Human Mesenchymal Stem Cells and Platelet-Derived Growth Factor on Human Retinal Ganglion Cells.

Authors:  Andrew Osborne; Julie Sanderson; Keith R Martin
Journal:  Stem Cells       Date:  2017-10-31       Impact factor: 6.277

10.  Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration.

Authors:  Manjit S Mehat; Venki Sundaram; Caterina Ripamonti; Anthony G Robson; Alexander J Smith; Shyamanga Borooah; Martha Robinson; Adam N Rosenthal; William Innes; Richard G Weleber; Richard W J Lee; Michael Crossland; Gary S Rubin; Baljean Dhillon; David H W Steel; Eddy Anglade; Robert P Lanza; Robin R Ali; Michel Michaelides; James W B Bainbridge
Journal:  Ophthalmology       Date:  2018-06-05       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.